aTyr Pharma, Inc. (ATYR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$6.03-2.43%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ATYR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -8.9% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
ATYR — litigation filed
Dated 2026-09-24
Other Events. On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease (Planned Phase 3 Study). The Company expects to focus on regulatory submissions in the U.S. and Europe as it initiates study-related activities in the fourth quarter…
Why it matters: The company said its cash can fund current operations into late 2028, but Phase 3 needs more money.
Worry ifaTyr reports that it must raise money for Phase 3 and announces an offering or debt deal that funds the trial.
Less concerning ifaTyr secures a grant, partner, or license deal for Phase 3, or reports cash support without a new share or debt sale.
Why it matters: The FDA aligned on the study plan. Starting the trial would move the lead program into its next test.
Supportive ifThe company reports that the Phase 3 study has started, with first patients enrolled, using the agreed plan.
Worry ifThe company reports a delay or a new FDA concern. Or no study starts after planned Q4 2026 study work.
Why it matters: The results will test efzofitimod in a second lung disease. The study enrolled 23 patients.
Watch forQ1 2027 results show a clear benefit on a reported lung or patient score at 270 mg or 450 mg versus placebo.
Also watch forResults show no benefit over placebo. Or the company delays its Q1 2027 report.
Why it matters: The company received a notice after its share price stayed below $1 for 30 business days. A fix would clear this listing concern.
Supportive ifNasdaq confirms ATYR has met its bid-price rule again.
Worry ifNasdaq gives a delisting notice. Or the company says it missed its deadline to meet the rules again.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$338 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $916 loss on $10,000 · 9.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,824 loss on $10,000 · 88.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.